A PP2A-mtATR-tBid axis links DNA damage-induced CIP2A degradation to apoptotic dormancy and therapeutic resistance in

Yibo Luo1, Himadri Biswas1, Yetunde Makinwa1

  • 1Department of Cell and Cancer Biology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, 43614, USA.

Cancer Letters
|May 12, 2025
PubMed

Insights

Researchers discovered a new way cancer cells resist chemotherapy. In pancreatic cancer, a protein complex (mtATR-tBid) stops cell death. Inhibiting this complex restores chemotherapy effectiveness against resistant tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Chemotherapy resistance is a major obstacle in cancer treatment, particularly for DNA damage-based drugs like gemcitabine.
  • Pancreatic ductal adenocarcinoma (PDAC) frequently develops resistance, necessitating novel therapeutic strategies.
  • Understanding non-DNA repair mechanisms of resistance is crucial for overcoming treatment failure.

Purpose of the Study:

  • To elucidate a novel non-DNA repair mechanism driving gemcitabine resistance in PDAC.
  • To identify therapeutic targets that can restore sensitivity to DNA damage-based chemotherapy.
  • To investigate the role of the CIP2A-PP2A-ATR axis in chemoresistance.

Main Methods:

  • Utilized gemcitabine-resistant PDAC cell lines and an orthotopic PDAC mouse model.
  • Investigated protein degradation pathways, phosphatase activity, and protein complex formation.
  • Employed PP2A inhibitor (LB-100) and specific antibodies to disrupt the identified complex.

Main Results:

  • Gemcitabine-resistant PDAC cells exhibit CIP2A degradation, leading to increased PP2A activity and cytoplasmic ATR dephosphorylation.
  • Dephosphorylated ATR forms a mitochondria-targeted antiapoptotic protein (mtATR), which complexes with tBid, inducing apoptotic dormancy.
  • Disruption of the mtATR-tBid complex by LB-100 or an ATR antibody restores apoptosis and inhibits tumor growth in vivo.

Conclusions:

  • A novel mechanism of chemoresistance involving CIP2A degradation, PP2A activation, and the formation of a pro-apoptotic complex (mtATR-tBid) was identified in PDAC.
  • Targeting the mtATR-tBid complex represents a promising strategy to overcome gemcitabine resistance.
  • LB-100 demonstrates efficacy by disrupting this complex, offering a potential therapeutic approach for resistant pancreatic cancer.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.1K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.2K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
2.8K